In the HER2 MUT NSCLC (n = 33), ORR was 66.7%, mDoR was 15.1 months, and mPFS was 11.3 months; in the naïve patients (n = 20), the ORR was 80%, mDOR was 19.9 months, and mPFS was 21.3 months. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.